Company intelligence / Profile preview

Helio Vision

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Helio Vision was a biotechnology company focused on developing therapies for proliferative vitreoretinopathy (PVR). Its lead asset, intravitreal methotrexate (now ADX-2191), a small molecule targeting dihydrofolate reductase, was Phase 3-ready and had Orphan Drug Designation. The company was acquired by Aldeyra Therapeutics in 2019.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Helio Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helio Vision.

Explore the full profile